Loading
SP
Salarius Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by HANISH ARNOLD C, was filed 24 Nov 2025.
Salarius Pharmaceuticals, Inc.: what insiders have been doing
Salarius Pharmaceuticals, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 23 October 2026, brought 4 filings signed by 2 insiders.
Purchases and sales both appear in the filings: 2 purchases (2 insiders, €17k) and 2 sales (1 insider, €15). Taken together, the purchases exceed the sales by €17k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 finance chief and 1 senior executive. Biggest ticket of the year: €14k, bought by Rosenblum Mark J and made public on 20 November 2025.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 24 November 2025, 334 days ago. Typically, a trade is published a median of 3 days after it takes place. Section 16 rules allow two business days to file each Form 4.
Compared with its exchange (3,167 companies, median 24 filings), a count of 4 filings is below the norm. The full history, which starts in 2016, counts 82 purchases against 5 sales.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
111
Thresholds
n/a
Buy Volume
€6M
82 ops. · all time
Sell Volume
€3M
5 ops. · all time
Who traded when
BuySaleArnold C. Hanish1 buy2 sales
Mark J. Rosenblum1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
Net income-US$10.8M
Last declaration on 2 January 2026
Declarations111 total
12 shares@ US$0.63970.0% of flowCommon StockSEC:0001615219-26-000004:1
15 shares@ US$0.63970.1% of flowCommon StockSEC:0001615219-26-000004:0
5,000 shares@ US$0.748124.4% of flowCommon StockSEC:0001615219-25-000193:0
Canonical exit: 18 Feb 2026 (T+90)
20,000 shares@ US$0.8019.2% of flowCommon StockSEC:0001615219-25-000177:0
Canonical exit: 18 Feb 2026 (T+90)
6,432 shares0Common StockSEC:0001615219-23-000025:0
14,300 shares0Common StockSEC:0001615219-23-000023:0
1,440 shares0Common StockSEC:0001615219-23-000013:0
1,440 shares0Common StockSEC:0001615219-23-000006:0
1,440 shares0Common StockSEC:0001615219-23-000010:0
20,000 shares0Common StockSEC:0001615219-23-000002:0
8,000 shares0Common StockSEC:0001615219-23-000004:0
1,440 shares0Common StockSEC:0001615219-23-000011:0
1,440 shares0Common StockSEC:0001615219-23-000015:0
1,440 shares0Common StockSEC:0001615219-23-000008:0
1,488 shares@ US$1.7343.6% of flowCommon StockSEC:0001615219-22-000153:0
2,693 shares@ US$1.7345.6% of flowCommon StockSEC:0001615219-22-000155:0
7,314 shares@ US$1.73417.9% of flowCommon StockSEC:0001615219-22-000141:0
10,000 shares@ US$1.73420.8% of flowCommon StockSEC:0001615219-22-000142:0
37,500 shares@ US$0.1871100.0% of flowCommon StockSEC:0001615219-22-000099:0
Canonical exit: 5 Sept 2022 (T+90)
27,700 shares@ US$0.18100.0% of flowCommon StockSEC:0001615219-22-000101:0
Canonical exit: 5 Sept 2022 (T+90)
26,553 shares@ US$0.1883100.0% of flowCommon StockSEC:0001615219-22-000097:0
Canonical exit: 4 Sept 2022 (T+90)
28,000 shares@ US$0.18436.0% of flowCommon StockSEC:0001615219-22-000095:0
Canonical exit: 1 Sept 2022 (T+90)
18,600 shares@ US$0.1823.2% of flowCommon StockSEC:0001615219-22-000087:1
Canonical exit: 24 Aug 2022 (T+90)
708 shares@ US$0.180.1% of flowCommon StockSEC:0001615219-22-000087:2
Canonical exit: 24 Aug 2022 (T+90)
10,392 shares@ US$0.17991.8% of flowCommon StockSEC:0001615219-22-000087:3
Canonical exit: 24 Aug 2022 (T+90)
25 of 111 declarations
About Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under ticker SLRX. The company has historically been headquartered in Houston, Texas, and has operated as a clinical-stage oncology developer focused on therapies that address dysregulated gene expression in hematologic malignancies and solid tumors. From an international equity perspective, Salarius fits the profile of a small-cap biotech whose valuation is primarily driven by clinical milestones, regulatory progress, capital markets access, and strategic transactions rather than commercial revenue.
Its core business has centered on two principal drug candidates built around protein inhibition and protein degradation. The best-known program is seclidemstat (SP-2577), an orally available LSD1 inhibitor that has been investigated in oncology settings with limited treatment options, including Ewing sarcoma and certain blood cancers. The second major asset is SP-3164, a targeted protein degrader designed to address difficult-to-drug cancer-related targets and to participate in the emerging targeted protein degradation field. Together, these programs positioned Salarius in a specialized segment of cancer drug development where scientific differentiation, intellectual property, and early clinical data are critical competitive variables.
Read moreShow less
Salarius does not compete with large diversified pharmaceutical companies on scale; instead, it competes within the highly competitive universe of development-stage biotech companies. That means its competitive position has depended on the quality of its science, the strength of its academic and clinical relationships, and its ability to raise capital through equity markets or strategic financing. Its geographic footprint has been largely U.S.-centric, with development, regulatory and clinical activities concentrated in the United States and supported by collaborations with research and medical institutions.
Recent developments have been especially material. In 2025, the company had to address NASDAQ listing compliance issues tied to both minimum bid price and stockholders’ equity requirements, culminating in a 1-for-15 reverse stock split in August 2025 to help restore compliance with the exchange’s minimum price standard. Separately, Salarius announced a definitive merger agreement with Decoy Therapeutics, a transaction intended to reshape the combined company’s platform and expand its pipeline into peptide conjugate therapeutics and applications in respiratory infectious diseases and gastrointestinal oncology. For investors in France, Belgium and Switzerland, this makes Salarius a high-risk, event-driven biotech name to monitor through SEC filings, clinical updates, financing news, and merger completion milestones. The company trades on the NASDAQ in the United States, and its profile remains that of a development-stage oncology biotech rather than a commercial-stage pharma business.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
